cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Corcept Therapeutics Inc
13 own
9 watching
Current Price
$59.99
$-2.3
(-3.69%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
3,688.58M
52-Week High
52-Week High
62.98000
52-Week Low
52-Week Low
20.84000
Average Volume
Average Volume
0.98M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
24.3094
iconMarket Capitalization3,688.58M
icon52-Week High62.98000
icon52-Week Low20.84000
iconAverage Volume0.98M
iconDividend Yield--
iconP/E Ratio24.3094
What does the Corcept Therapeutics Inc do?
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer. In addition, it develops CORT125134 for the treatment of patients with Cushing's syndrome and solid-tumor cancers; and CLIA-validated assay to measure expression of the gene FKBP5, which is stimulated by cortisol activity at glucocorticoid receptor. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Read More
How much money does Corcept Therapeutics Inc make?
News & Events about Corcept Therapeutics Inc.
Ticker Report
1 year ago
Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT Get Rating) have been assigned an average recommendation of Hold from the seven ratings firms that are presently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold ...
Globe Newswire
1 year ago
MENLO PARK, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT) (Corcept), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects ...
Globe Newswire
1 year ago
MENLO PARK, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the ...
Globe Newswire
2years ago
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Dec. 29, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Corcept Therapeutics Inc. (Corcept or the Company) (NASDAQ: CORT) investors that the firm has initiated an investigation into possible...
Business Wire
2years ago
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (Corcept or the Company) (NASDAQ: CORT) for violations of the securities laws. The investigation focuses on whether the Company...
Frequently Asked Questions
Frequently Asked Questions
What is Corcept Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Corcept Therapeutics Inc shares?
plus_minus_icon
How can I buy Corcept Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Corcept Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Corcept Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Corcept Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Corcept Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Corcept Therapeutics Inc?
plus_minus_icon
What percentage is Corcept Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Corcept Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$59.99
$-2.3
(-3.69%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
$34.46
$-0.92 (-2.60 %)
Glaukos Corp
Glaukos Corp
$160.22
$-1.00 (-0.62 %)
Galapagos NV
Galapagos NV
$23.70
$-0.04 (-0.17 %)
TG Therapeutics Inc
TG Therapeutics Inc
$31.27
$2.23 (7.68 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
$34.46
$-0.92 (-2.60 %)
Glaukos Corp
Glaukos Corp
$160.22
$-1.00 (-0.62 %)
Galapagos NV
Galapagos NV
$23.70
$-0.04 (-0.17 %)
TG Therapeutics Inc
TG Therapeutics Inc
$31.27
$2.23 (7.68 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00